search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size
  • FDA warns health care professionals not to inject patients with IV solutions from Wallcur, of San Diego

    FDA issued an update on 1/14/15:
    http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm

    The U.S. Food and Drug Administration is alerting health care professionals not to use Wallcur, LLC, simulated intravenous (IV) products in human or animal patients. These products are for training purposes only.

    Before administering IV solutions to patients, health care providers should carefully check the labels to ensure that the products are not training products, such as Practi IV Solution Bags marketed by Wallcur. Wallcur’s training products, which may bear the words “for clinical simulation,” are not to be administered to patients.
     
    FDA has become aware that some Wallcur training IV products have been distributed to health care facilities and administered to patients. There have been reports of serious adverse events associated with the use of certain of these products – i.e., Practi IV Solution Bags.

    If you suspect that any Wallcur training IV products may have been administered to a patient, whether or not the incident has resulted in an adverse event, please report the incident to FDA’s MedWatch Adverse Event Reporting program by:


    FDA will continue to investigate and monitor this issue. The agency is also working with the Centers for Disease Control and Prevention to inform health care professionals and state health departments.

| HIVMA | Contact Us

© Copyright IDSA 2018 Infectious Diseases Society of America

Full Site Mobile Site